Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.45 USD | +0.44% | -8.81% | -38.56% |
May. 24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
May. 24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.48B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M | |
-6.56% | 273M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023